← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Zacharon Pharmaceuticals, Inc.
San Diego, CA
$5,793,280
Total funding
12
Grants
Funding over time
peak $1.6M · FY2005–12$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$5,793,280 · 12
By mechanism
R44$3,629,671 · 2
R43$1,913,609 · 8
R21$250,000 · 2
Investigators at Zacharon Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,781
R44 · FY2012 · NS
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$999,327
R44 · FY2011 · NS
Development of Novel Inhibitors of Ganglioside Biosynthesis$697,057
R44 · FY2008 · CA
Development of Novel Inhibitors of Ganglioside Biosynthesis$652,045
R44 · FY2009 · CA
A Novel Small Molecule Therapy for Tay-Sachs and Sandhoff Diseases$342,896
R43 · FY2011 · NS
Substrate Optimization Therapy: A Novel Therapy for Mucopolysaccharidosis$339,513
R43 · FY2010 · NS
Development of a Novel Biomarker for Mucopolysaccharidosis I, II, and VI$335,739
R43 · FY2012 · NS
Development of a Small Molecule Therapy for Metachromatic Leukodystrophy$296,236
R43 · FY2012 · NS
Inhibitors of Heparan Sulfate Biosynthesis and Cancer$196,245
R43 · FY2006 · CA
Structure-activity relationship study of an inhibitor of tumor metastasis$188,112
R43 · FY2008 · CA
Development of Novel Inhibitors of Ganglioside Biosynthesis$175,000
R44 · FY2010 · CA
Cell-Based Screen-Inhibitors of Mucin-Type O-Linked(RMI)$125,000
R21 · FY2005 · NS
Development of cell-based assays for discovery of GIcNAc-TV inhibitors.$125,000
R21 · FY2006 · NS
Chondroitin Sulfate Inhibitor Screen for Neural-Regeneration Drugs$114,868
R43 · FY2006 · NS
Development of Novel Inhibitors of Ganglioside Biosynthesis$106,461
R44 · FY2010 · CA
Development of a cell-based screen for inhibitors of ganglioside biosynthesis$100,000
R43 · FY2006 · CA